Free Trial

Novo Nordisk A/S (NVO) Financials

Novo Nordisk A/S logo
$62.07 -0.56 (-0.89%)
Closing price 03:59 PM Eastern
Extended Trading
$62.10 +0.03 (+0.05%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for Novo Nordisk A/S

Annual Income Statements for Novo Nordisk A/S

This table shows Novo Nordisk A/S's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Income / (Loss) Attributable to Common Shareholders
5,853 6,926 7,269 7,988 12,418 14,017
Consolidated Net Income / (Loss)
5,853 6,926 7,269 7,988 12,418 14,017
Net Income / (Loss) Continuing Operations
5,853 6,926 7,269 7,988 12,418 14,017
Total Pre-Tax Income
7,295 8,733 8,992 9,935 15,533 17,654
Total Operating Income
7,886 8,897 8,925 10,762 15,221 17,813
Total Gross Profit
15,316 17,425 17,829 21,363 29,159 34,128
Total Revenue
18,344 20,866 21,429 25,456 34,466 40,308
Operating Revenue
18,344 20,866 21,429 25,456 34,466 40,308
Total Cost of Revenue
3,619 3,441 3,601 4,092 5,307 6,180
Operating Cost of Revenue
3,619 3,441 3,601 4,092 5,307 6,180
Total Operating Expenses
7,430 8,529 8,903 10,602 13,937 16,315
Selling, General & Admin Expense
5,384 6,063 6,249 7,291 9,141 9,352
Research & Development Expense
2,137 2,541 2,705 3,459 4,814 6,671
Other Operating Expenses / (Income)
-90 -76 -51 -149 -18 292
Total Other Income / (Expense), net
0.00 -164 66 -827 312 -159
Interest Expense
- 431 373 861 125 1,020
Interest & Investment Income
- 268 439 34 437 860
Income Tax Expense
1,443 1,807 1,723 1,947 3,115 3,637
Basic Earnings per Share
$16.41 $18.05 $10.40 $1.76 $2.77 $3.15
Weighted Average Basic Shares Outstanding
- - 2.31B 2280T 4.51B 4.47B
Diluted Earnings per Share
$16.38 $18.01 $10.37 $1.76 $2.76 $3.14
Weighted Average Diluted Shares Outstanding
- - 2.31B 2280T 4.51B 4.47B
Weighted Average Basic & Diluted Shares Outstanding
- - 2.31B 2280T 4.51B 4.47B

Quarterly Income Statements for Novo Nordisk A/S

No quarterly income statements for Novo Nordisk A/S are available.


Annual Cash Flow Statements for Novo Nordisk A/S

This table details how cash moves in and out of Novo Nordisk A/S's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2021 2022 2023 2024
Net Change in Cash & Equivalents
1,695 -449 1,562 312 5,014 5,321
Net Cash From Operating Activities
8,369 8,539 9,189 11,348 18,216 22,000
Net Cash From Continuing Operating Activities
8,369 8,523 9,189 11,309 18,216 16,790
Net Income / (Loss) Continuing Operations
5,853 6,926 7,269 7,988 12,418 14,017
Consolidated Net Income / (Loss)
5,853 6,926 7,269 7,988 12,418 14,017
Depreciation Expense
851 946 917 1,059 1,397 2,652
Non-Cash Adjustments To Reconcile Net Income
732 720 659 4,389 3,272 3,358
Changes in Operating Assets and Liabilities, net
934 -69 344 -2,127 1,129 1,972
Net Cash From Investing Activities
-1,341 -3,688 -3,747 -3,585 -3,829 -17,891
Net Cash From Continuing Investing Activities
-1,341 -3,628 -3,747 -3,140 -3,829 -17,891
Purchase of Property, Plant & Equipment
-1,342 -2,672 -964 -375 -3,829 -6,546
Acquisitions
0.00 0.00 -2,783 -1,018 0.00 -11,404
Net Cash From Financing Activities
-5,332 -5,300 -3,880 -7,451 -9,372 1,212
Net Cash From Continuing Financing Activities
-5,332 -5,300 -3,880 -7,451 -9,372 1,212
Repayment of Debt
-124 -156 -1,018 -1,960 -218 -879
Repurchase of Common Equity
-2,304 -2,770 -2,960 -3,465 -4,441 -2,801
Payment of Dividends
-2,916 -3,307 -3,275 -3,640 -4,714 -6,127
Issuance of Debt
12 934 3,373 1,613 0.00 11,019
Cash Interest Paid
31 - 40 - 73 85
Cash Interest Received
9.62 16 37 40 159 261
Cash Income Taxes Paid
- - 2,197 - 3,843 4,113

Quarterly Cash Flow Statements for Novo Nordisk A/S

No quarterly cash flow statements for Novo Nordisk A/S are available.


Annual Balance Sheets for Novo Nordisk A/S

This table presents Novo Nordisk A/S's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Total Assets
23,821 29,604 34,706 46,668 64,652
Total Current Assets
10,817 13,027 15,564 20,723 22,333
Short-Term Investments
383 257 392 348 878
Accounts Receivable
4,559 6,186 7,273 9,612 9,987
Inventories, net
3,047 2,986 3,508 4,721 5,670
Prepaid Expenses
- 767 864 1,197 1,751
Current Deferred & Refundable Income Taxes
48 170 135 360 396
Plant, Property, & Equipment, net
8,263 8,426 9,591 0.00 0.00
Total Noncurrent Assets
4,535 8,030 9,474 12,174 19,154
Intangible Assets
3,395 6,571 7,328 8,964 15,419
Noncurrent Deferred & Refundable Income Taxes
964 1,320 2,000 3,024 3,418
Other Noncurrent Operating Assets
175 139 146 - 316
Total Liabilities & Shareholders' Equity
23,821 29,604 34,706 46,668 64,652
Total Liabilities
13,412 18,836 22,696 30,855 44,737
Total Current Liabilities
11,551 15,146 17,398 25,176 30,193
Short-Term Debt
1,450 2,415 629 1,150 2,865
Accounts Payable
940 1,350 2,242 3,800 4,004
Current Deferred & Payable Income Tax Liabilities
643 557 1,020 1,056 1,349
Other Current Liabilities
8,517 10,824 13,507 19,170 21,975
Total Noncurrent Liabilities
1,861 3,690 5,298 5,679 14,544
Long-Term Debt
476 1,973 3,498 3,046 12,447
Noncurrent Deferred & Payable Income Tax Liabilities
411 802 1,016 1,508 753
Noncurrent Employee Benefit Liabilities
230 195 110 110 125
Other Noncurrent Operating Liabilities
744 721 675 1,015 1,218
Total Equity & Noncontrolling Interests
10,409 10,767 12,010 15,813 19,916
Total Preferred & Common Equity
10,708 10,767 12,010 15,813 19,916
Total Common Equity
10,708 10,767 12,010 15,813 19,916
Common Stock
77 70 66 67 62
Retained Earnings
10,482 10,959 11,593 15,558 20,049
Treasury Stock
-1.31 -0.91 -0.86 -0.74 -0.28
Other Equity Adjustments
150 -261 352 189 -195

Quarterly Balance Sheets for Novo Nordisk A/S

This table presents Novo Nordisk A/S's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q4 2020 Q4 2021 Q4 2022 Q4 2023 Q4 2024
Total Assets
23,821 29,604 34,706 46,668 64,652
Total Current Assets
10,817 13,027 15,564 20,723 22,333
Short-Term Investments
383 257 392 348 878
Accounts Receivable
4,559 6,186 7,273 9,612 9,987
Inventories, net
3,047 2,986 3,508 4,721 5,670
Prepaid Expenses
- 767 864 1,197 1,751
Current Deferred & Refundable Income Taxes
48 170 135 360 396
Plant, Property, & Equipment, net
8,263 8,426 9,591 0.00 0.00
Total Noncurrent Assets
4,535 8,030 9,474 12,174 19,154
Intangible Assets
3,395 6,571 7,328 8,964 15,419
Noncurrent Deferred & Refundable Income Taxes
964 1,320 2,000 3,024 3,418
Other Noncurrent Operating Assets
175 139 146 - 316
Total Liabilities & Shareholders' Equity
23,821 29,604 34,706 46,668 64,652
Total Liabilities
13,412 18,836 22,696 30,855 44,737
Total Current Liabilities
11,551 15,146 17,398 25,176 30,193
Short-Term Debt
1,450 2,415 629 1,150 2,865
Accounts Payable
940 1,350 2,242 3,800 4,004
Current Deferred & Payable Income Tax Liabilities
643 557 1,020 1,056 1,349
Other Current Liabilities
8,517 10,824 13,507 19,170 21,975
Total Noncurrent Liabilities
1,861 3,690 5,298 5,679 14,544
Long-Term Debt
476 1,973 3,498 3,046 12,447
Noncurrent Deferred & Payable Income Tax Liabilities
411 802 1,016 1,508 753
Noncurrent Employee Benefit Liabilities
230 195 110 110 125
Other Noncurrent Operating Liabilities
744 721 675 1,015 1,218
Total Equity & Noncontrolling Interests
10,409 10,767 12,010 15,813 19,916
Total Preferred & Common Equity
10,708 10,767 12,010 15,813 19,916
Total Common Equity
10,708 10,767 12,010 15,813 19,916
Common Stock
77 70 66 67 62
Retained Earnings
10,482 10,959 11,593 15,558 20,049
Treasury Stock
-1.31 -0.91 -0.86 -0.74 -0.28
Other Equity Adjustments
150 -261 352 189 -195

Annual Metrics and Ratios for Novo Nordisk A/S

This table displays calculated financial ratios and metrics derived from Novo Nordisk A/S's official financial filings.

Metric 2019 2020 2021 2022 2023 2024
Growth Metrics
- - - - - -
Revenue Growth
0.00% 13.75% 2.70% 18.79% 35.40% 16.95%
EBITDA Growth
0.00% 12.66% 0.00% 20.10% 40.58% 23.15%
EBIT Growth
0.00% 12.82% 0.32% 20.57% 41.44% 17.03%
NOPAT Growth
0.00% 11.53% 2.25% 19.92% 40.64% 16.23%
Net Income Growth
0.00% 18.34% 4.94% 9.89% 55.47% 12.88%
EPS Growth
0.00% 9.95% 4.94% 9.89% 57.18% 13.68%
Operating Cash Flow Growth
0.00% 2.04% 7.61% 23.50% 60.52% 20.77%
Free Cash Flow Firm Growth
0.00% 0.00% 312.89% 108.99% 173.52% -66.29%
Invested Capital Growth
0.00% 0.00% 35.15% 1.32% -90.07% 518.17%
Revenue Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profitability Metrics
- - - - - -
Gross Margin
83.49% 83.51% 83.20% 83.92% 84.60% 84.67%
EBITDA Margin
47.63% 47.17% 45.93% 46.44% 48.22% 50.77%
Operating Margin
42.99% 42.64% 41.65% 42.28% 44.16% 44.19%
EBIT Margin
42.99% 42.64% 41.65% 42.28% 44.16% 44.19%
Profit (Net Income) Margin
31.90% 33.19% 33.92% 31.38% 36.03% 34.78%
Tax Burden Percent
80.22% 79.31% 80.83% 80.40% 79.95% 79.40%
Interest Burden Percent
92.51% 98.16% 100.74% 92.32% 102.05% 99.11%
Effective Tax Rate
19.78% 20.69% 19.17% 19.60% 20.05% 20.60%
Return on Invested Capital (ROIC)
0.00% 157.42% 68.45% 70.94% 180.35% 323.26%
ROIC Less NNEP Spread (ROIC-NNEP)
0.00% 175.40% -44.24% -11.36% 176.87% 324.20%
Return on Net Nonoperating Assets (RNNOA)
0.00% -24.33% 0.20% -0.81% -91.08% -244.80%
Return on Equity (ROE)
0.00% 133.08% 68.65% 70.14% 89.26% 78.46%
Cash Return on Invested Capital (CROIC)
0.00% -42.58% 38.55% 69.63% 344.23% 178.96%
Operating Return on Assets (OROA)
0.00% 37.35% 33.41% 33.47% 37.41% 32.00%
Return on Assets (ROA)
0.00% 29.08% 27.21% 24.84% 30.52% 25.18%
Return on Common Equity (ROCE)
0.00% 136.91% 69.62% 70.14% 89.26% 78.46%
Return on Equity Simple (ROE_SIMPLE)
0.00% 64.68% 67.50% 66.51% 78.53% 70.38%
Net Operating Profit after Tax (NOPAT)
6,326 7,056 7,215 8,652 12,169 14,144
NOPAT Margin
34.49% 33.82% 33.67% 33.99% 35.31% 35.09%
Net Nonoperating Expense Percent (NNEP)
0.00% -17.98% 112.69% 82.30% 3.48% -0.94%
Return On Investment Capital (ROIC_SIMPLE)
- 57.20% 47.61% 53.62% 60.82% 40.15%
Cost of Revenue to Revenue
19.73% 16.49% 16.80% 16.08% 15.40% 15.33%
SG&A Expenses to Revenue
29.35% 29.06% 29.16% 28.64% 26.52% 23.20%
R&D to Revenue
11.65% 12.18% 12.62% 13.59% 13.97% 16.55%
Operating Expenses to Revenue
40.50% 40.87% 41.55% 41.65% 40.44% 40.48%
Earnings before Interest and Taxes (EBIT)
7,886 8,897 8,925 10,762 15,221 17,813
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
8,736 9,842 9,842 11,821 16,618 20,466
Valuation Ratios
- - - - - -
Price to Book Value (P/BV)
0.00 0.00 11,562,076.90 12,547,067.02 29.18 19.48
Price to Tangible Book Value (P/TBV)
0.00 0.00 29,663,488.40 32,184,362.22 67.38 86.28
Price to Revenue (P/Rev)
0.00 0.00 5,809,450.94 5,919,642.60 13.39 9.62
Price to Earnings (P/E)
0.00 0.00 17,127,765.41 18,865,455.88 37.16 27.68
Dividend Yield
2.29% 1.97% 1.37% 1.21% 0.00% 1.68%
Earnings Yield
0.00% 0.00% 0.00% 0.00% 2.69% 3.61%
Enterprise Value to Invested Capital (EV/IC)
0.00 0.00 10,274,981.41 12,274,627.82 381.76 53.42
Enterprise Value to Revenue (EV/Rev)
0.00 0.00 5,809,451.14 5,919,642.75 13.50 9.98
Enterprise Value to EBITDA (EV/EBITDA)
0.00 0.00 12,648,575.36 12,747,860.72 27.99 19.66
Enterprise Value to EBIT (EV/EBIT)
0.00 0.00 13,948,071.75 14,002,385.59 30.56 22.59
Enterprise Value to NOPAT (EV/NOPAT)
0.00 0.00 17,255,105.62 17,416,168.46 38.22 28.45
Enterprise Value to Operating Cash Flow (EV/OCF)
0.00 0.00 13,548,618.09 13,278,543.53 25.54 18.29
Enterprise Value to Free Cash Flow (EV/FCFF)
0.00 0.00 30,638,061.71 17,745,057.43 20.03 51.39
Leverage & Solvency
- - - - - -
Debt to Equity
0.00 0.19 0.41 0.34 0.27 0.77
Long-Term Debt to Equity
0.00 0.05 0.18 0.29 0.19 0.63
Financial Leverage
0.00 -0.14 0.00 0.07 -0.52 -0.76
Leverage Ratio
0.00 2.29 2.52 2.82 2.92 3.12
Compound Leverage Factor
0.00 2.25 2.54 2.61 2.98 3.09
Debt to Total Capital
0.00% 15.62% 28.95% 25.57% 20.97% 43.47%
Short-Term Debt to Total Capital
0.00% 11.76% 15.94% 3.89% 5.75% 8.13%
Long-Term Debt to Total Capital
0.00% 3.86% 13.02% 21.68% 15.22% 35.33%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
0.00% 86.81% 71.05% 74.43% 79.03% 56.53%
Debt to EBITDA
0.00 0.20 0.45 0.35 0.25 0.75
Net Debt to EBITDA
0.00 -0.06 0.42 0.32 0.22 0.71
Long-Term Debt to EBITDA
0.00 0.05 0.20 0.30 0.18 0.61
Debt to NOPAT
0.00 0.27 0.61 0.48 0.34 1.08
Net Debt to NOPAT
0.00 -0.08 0.57 0.43 0.30 1.02
Long-Term Debt to NOPAT
0.00 0.07 0.27 0.40 0.25 0.88
Altman Z-Score
0.00 0.00 3,965,536.12 3,983,640.87 11.14 7.02
Noncontrolling Interest Sharing Ratio
0.00% -2.88% -1.41% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - -
Current Ratio
0.00 0.94 0.86 0.89 0.82 0.74
Quick Ratio
0.00 0.61 0.43 0.44 0.40 0.36
Cash Flow Metrics
- - - - - -
Free Cash Flow to Firm (FCFF)
0.00 -1,909 4,063 8,492 23,227 7,830
Operating Cash Flow to CapEx
623.84% 235.35% 953.01% 534.72% 475.68% 336.06%
Free Cash Flow to Firm to Interest Expense
0.00 -4.43 10.89 9.86 185.23 7.68
Operating Cash Flow to Interest Expense
0.00 19.80 24.63 13.18 145.27 21.58
Operating Cash Flow Less CapEx to Interest Expense
0.00 11.39 22.05 10.71 114.73 15.16
Efficiency Ratios
- - - - - -
Asset Turnover
0.00 0.88 0.80 0.79 0.85 0.72
Accounts Receivable Turnover
0.00 4.58 3.99 3.78 4.08 4.11
Inventory Turnover
0.00 1.13 1.19 1.26 1.29 1.19
Fixed Asset Turnover
0.00 2.53 2.57 2.83 0.00 0.00
Accounts Payable Turnover
0.00 3.66 3.15 2.28 1.76 1.58
Days Sales Outstanding (DSO)
0.00 79.74 91.50 96.49 89.41 88.73
Days Inventory Outstanding (DIO)
0.00 323.22 305.78 289.63 282.96 306.85
Days Payable Outstanding (DPO)
0.00 99.69 116.05 160.20 207.77 230.46
Cash Conversion Cycle (CCC)
0.00 303.27 281.23 225.92 164.60 165.13
Capital & Investment Metrics
- - - - - -
Invested Capital
0.00 8,965 12,116 12,277 1,218 7,532
Invested Capital Turnover
0.00 4.66 2.03 2.09 5.11 9.21
Increase / (Decrease) in Invested Capital
0.00 8,965 3,152 160 -11,058 6,314
Enterprise Value (EV)
0.00 0.00 124,493,291,098 150,689,711,919 465,156 402,384
Market Capitalization
0.00 0.00 124,493,286,967 150,689,708,184 461,494 387,950
Book Value per Share
$0.00 $0.00 $4.66 $0.00 $0.00 $4.42
Tangible Book Value per Share
$0.00 $0.00 $1.82 $0.00 $0.00 $1.00
Total Capital
0.00 12,335 15,155 16,137 20,009 35,228
Total Debt
0.00 1,927 4,388 4,127 4,196 15,312
Total Long-Term Debt
0.00 476 1,973 3,498 3,046 12,447
Net Debt
0.00 -554 4,130 3,734 3,663 14,434
Capital Expenditures (CapEx)
1,341 3,628 964 2,122 3,829 6,546
Debt-free, Cash-free Net Working Capital (DFCFNWC)
0.00 -1,764 39 -1,597 -3,651 -5,873
Debt-free Net Working Capital (DFNWC)
0.00 717 296 -1,205 -3,303 -4,995
Net Working Capital (NWC)
0.00 -734 -2,119 -1,834 -4,453 -7,860
Net Nonoperating Expense (NNE)
474 130 -54 665 -249 127
Net Nonoperating Obligations (NNO)
0.00 -1,444 1,349 267 -14,595 -12,384
Total Depreciation and Amortization (D&A)
851 946 917 1,059 1,397 2,652
Debt-free, Cash-free Net Working Capital to Revenue
0.00% -8.45% 0.18% -6.28% -10.59% -14.57%
Debt-free Net Working Capital to Revenue
0.00% 3.43% 1.38% -4.73% -9.58% -12.39%
Net Working Capital to Revenue
0.00% -3.52% -9.89% -7.20% -12.92% -19.50%
Earnings Adjustments
- - - - - -
Adjusted Basic Earnings per Share
$0.00 $0.00 $0.00 $12.26 $18.67 $3.15
Adjusted Weighted Average Basic Shares Outstanding
0.00 0.00 0.00 4560T 4.51B 4.47B
Adjusted Diluted Earnings per Share
$0.00 $0.00 $0.00 $12.22 $18.62 $3.14
Adjusted Weighted Average Diluted Shares Outstanding
0.00 0.00 0.00 4560T 4.51B 4.47B
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
0.00 0.00 0.00 4560T 4.51B 4.47B
Normalized Net Operating Profit after Tax (NOPAT)
6,326 7,056 7,215 8,652 12,169 14,144
Normalized NOPAT Margin
34.49% 33.82% 33.67% 33.99% 35.31% 35.09%
Pre Tax Income Margin
39.77% 41.85% 41.96% 39.03% 45.07% 43.80%
Debt Service Ratios
- - - - - -
EBIT to Interest Expense
0.00 20.63 23.93 12.50 121.39 17.47
NOPAT to Interest Expense
0.00 16.36 19.34 10.05 97.05 13.87
EBIT Less CapEx to Interest Expense
0.00 12.21 21.34 10.03 90.85 11.05
NOPAT Less CapEx to Interest Expense
0.00 7.95 16.76 7.58 66.51 7.45
Payout Ratios
- - - - - -
Dividend Payout Ratio
49.83% 47.75% 45.06% 45.57% 37.96% 43.71%
Augmented Payout Ratio
89.20% 87.75% 85.78% 88.95% 73.72% 63.69%

Quarterly Metrics and Ratios for Novo Nordisk A/S

No quarterly metrics and ratios for Novo Nordisk A/S are available.


Frequently Asked Questions About Novo Nordisk A/S's Financials

When does Novo Nordisk A/S's financial year end?

According to the most recent income statement we have on file, Novo Nordisk A/S's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Novo Nordisk A/S's net income changed over the last 5 years?

Novo Nordisk A/S's net income appears to be on an upward trend, with a most recent value of $14.02 billion in 2024, rising from $5.85 billion in 2019. The previous period was $12.42 billion in 2023.

What is Novo Nordisk A/S's operating income?
Novo Nordisk A/S's total operating income in 2024 was $17.81 billion, based on the following breakdown:
  • Total Gross Profit: $34.13 billion
  • Total Operating Expenses: $16.31 billion
How has Novo Nordisk A/S revenue changed over the last 5 years?

Over the last 5 years, Novo Nordisk A/S's total revenue changed from $18.34 billion in 2019 to $40.31 billion in 2024, a change of 119.7%.

How much debt does Novo Nordisk A/S have?

Novo Nordisk A/S's total liabilities were at $44.74 billion at the end of 2024, a 45.0% increase from 2023, and a 233.6% increase since 2020.

How has Novo Nordisk A/S's book value per share changed over the last 5 years?

Over the last 5 years, Novo Nordisk A/S's book value per share changed from 0.00 in 2019 to 4.42 in 2024, a change of 441.6%.



This page (NYSE:NVO) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners